Skip to main content
SpringerLink
Log in

Diagnostik: Blutbasierte Marker

  • Chapter
  • First Online:
Nicht-alkoholische Fettlebererkrankung

  • 982 Accesses

Zusammenfassung

In der Diagnostik der nicht-alkoholischen Fettlebererkrankung (NAFLD) kommt es neben der Klärung der Ätiologie und Bestimmung des Fibrosestadiums auf die frühzeitige Identifikation der Patienten an, bei denen ein signifikanter Progress zu erwarten ist. Insbesondere die Differenzierung zwischen der unkomplizierten Fettleber (NAFL) und der nicht-alkoholischen Steatohepatitis (NASH) ist prognostisch bedeutsam, gelingt aber mit Standardlaborparametern nicht, sondern ist allein histologisch zu erreichen. Der Nachweis von K-18-Fragmenten, die bei der Apoptose von Hepatozyten entstehen, durch den M30-Biomarker stellt einen durch verschiedene Studien gut belegten Weg dar, progressionsgefährdete NAFLD-Patienten frühzeitig im Krankheitsgeschehen zu identifizieren. Dieser Abschnitt entspricht der Zusammenfassung und macht somit keinen Sinn (redundant)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Alexander M, Loomis AK, Fairburn-Beech J et al (2018) Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med 16(1):130

    Article  PubMed  PubMed Central  Google Scholar 

  • Angulo P, Hui JM, Marchesini G et al (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846–854

    Article  CAS  PubMed  Google Scholar 

  • Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389–397

    PubMed  Google Scholar 

  • Anty R, Iannelli A, Patouraux S et al (2010) A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 32:1315–1322

    Article  CAS  PubMed  Google Scholar 

  • Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690

    Article  CAS  PubMed  Google Scholar 

  • Bantel H, Ruck P, Schulze-Osthoff K (2000) In situ monitoring of caspase activation in hepatobiliary diseases. Cell Death Differ 7:504–505

    Article  CAS  PubMed  Google Scholar 

  • Bantel H, Lügering A, Heidemann J et al (2004) Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40:1078–1087

    Article  CAS  PubMed  Google Scholar 

  • Bantel H, John K, Schulze-Osthoff K (2014) Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments. Am J Gastroenterol 109:140–141

    Article  CAS  PubMed  Google Scholar 

  • Bechmann LP, Kocabayoglu P, Sowa JP et al (2013) Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 57:1394–1406

    Article  CAS  PubMed  Google Scholar 

  • Boursier J, Vergniol J, Guillet A et al (2016) Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 65:570–578

    Article  PubMed  Google Scholar 

  • Boursier J, Anty R, Vonghia L et al (2018) Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther 47:1387–1396

    Article  CAS  PubMed  Google Scholar 

  • Canbay A, Feldstein A, Kronenberger B et al (2014) Cytokeratin 18 as marker for non-invasive diagnosis and prognosis of acute and chronic liver diseases. Z Gastroenterol 52:290–295

    Article  CAS  PubMed  Google Scholar 

  • Canbay A, Kälsch J, Neumann U et al (2019) Non-invasive assessment of NAFLD as systemic disease-A machine learning perspective. PLoS ONE 14:e0214436

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Castéra L, Vilgrain V, Angulo P (2013) Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 10:666–675

    Article  PubMed  CAS  Google Scholar 

  • Castéra L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156:1264–1281

    Article  PubMed  Google Scholar 

  • Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357

    Article  PubMed  Google Scholar 

  • Daniels SJ, Leeming DJ, Eslam M et al (2019) ADAPT: an algorithm incorporating PRO-C3 XE „PRO-C3“ accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 69:1075–1086

    Article  CAS  PubMed  Google Scholar 

  • Demir M, Lang S, Nierhoff D et al (2013) Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease. J Clin Gastroenterol 47:719–726

    Article  PubMed  Google Scholar 

  • Diab DL, Yerian L, Schauer P et al (2008) Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6:1249–1254

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100

    Article  CAS  PubMed  Google Scholar 

  • Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:1557–1565

    Article  CAS  PubMed  Google Scholar 

  • European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402

    Google Scholar 

  • Ekstedt M, Hagström H, Nasr P et al (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:1547–1554

    Article  CAS  PubMed  Google Scholar 

  • Feldstein AE, Wieckowska A, Lopez AR et al (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50:1072–1078

    Article  CAS  PubMed  Google Scholar 

  • Feldstein AE, Alkhouri N, De Vito R et al (2013) Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 108:1526–1531

    Article  CAS  PubMed  Google Scholar 

  • Festi D, Schiumerini R, Marzi L et al (2013) The diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 37:392–400

    Article  CAS  PubMed  Google Scholar 

  • Fitzpatrick E, Mitry RR, Quaglia A et al (2010) Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. JPGN 15:500–506

    Google Scholar 

  • Fracanzani AL, Valenti L, Bugianesi E et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48:792–798

    Article  CAS  PubMed  Google Scholar 

  • Friedman SL, Ratziu V, Harrison SA et al (2018) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67:1754–1767

    Article  CAS  PubMed  Google Scholar 

  • Gholam PM, Flancbaum L, Machan JT et al (2007) Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 102:399–408

    Article  CAS  PubMed  Google Scholar 

  • Hsu C, Caussy C, Imajo K et al (2019) Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17:630–637

    Article  PubMed  Google Scholar 

  • Hyysalo J, Männistö VT, Zhou Y et al (2014) A population-based study on the prevalence of NASH using scores validated against liver histology. J Hepatol 60:839–846

    Article  PubMed  Google Scholar 

  • Joka D, Wahl K, Moeller S et al (2012) Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology 55:455–464

    Article  CAS  PubMed  Google Scholar 

  • Karsdal MA, Henriksen K, Nielsen MJ et al (2016) Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol 311:G1009–G1017

    Article  PubMed  Google Scholar 

  • Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321

    Article  PubMed  Google Scholar 

  • Ku NO, Strnad P, Bantel H et al (2016) Keratins: biomarkers and modulators of apoptotic and necrotic cell death in the liver. Hepatology 64:966–976

    Article  CAS  PubMed  Google Scholar 

  • Labenz C, Huber Y, Kalliga E et al (2018) Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther 48:1109–1116

    Article  CAS  PubMed  Google Scholar 

  • Leers MP, Kölgen W, Björklund V et al (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567–572

    Article  CAS  PubMed  Google Scholar 

  • Liebig S, Stoeckmann N, Geier A et al (2019) Multicenter validation study of a diagnostic algorithm to detect NASH and fibrosis in NAFLD patients with low NAFLD fibrosis score or liver stiffness. Clin Transl Gastroenterol 10(8):e00066

    Article  PubMed  PubMed Central  Google Scholar 

  • Machado MV, Cortez-Pinto H (2013) Non-invasive diagnosis of non-alcoholic fatty liver disease. A Critical Appraisal. J Hepatol 58:1007–1019

    PubMed  Google Scholar 

  • Mofrad P, Contos MJ, Haque M et al (2003) Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286–1292

    Article  PubMed  Google Scholar 

  • Musso G, Gambino R, Cassader M et al (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617–649

    Article  PubMed  Google Scholar 

  • Ong JP, Pitts A, Younossi ZM (2008) Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49:608–612

    Article  PubMed  Google Scholar 

  • Palekar NA, Naus R, Larson SP et al (2006) Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26:151–156

    Article  PubMed  Google Scholar 

  • Petta S, Vanni E, Bugianesi E et al (2015) The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 35:1566–1573

    Article  PubMed  Google Scholar 

  • Poynard T, Ratziu V, Charlotte F et al (2006) Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:34

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Roeb E, Steffen HM, Bantel H et al (2015) S2K guideline non-alcoholic fatty liver disease. Z Gastroenterol 53:668–723

    Article  CAS  PubMed  Google Scholar 

  • Schuppan D, Surabattula R, Wang XY (2018) Determinants of fibrosis progression and regression in NASH. J Hepatol 68:238–250

    Article  CAS  PubMed  Google Scholar 

  • Shen J, Chan HL, Wong GL et al (2012) Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment Pharmacol Ther 36:1057–1066

    Article  CAS  PubMed  Google Scholar 

  • Sumida Y, Yoneda M, Hyogo H et al (2011) A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 46:257–268

    Article  CAS  PubMed  Google Scholar 

  • Tamimi TI, Elgouhari HM, Alkhouri N et al (2011) An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 54:1224–1229

    Article  PubMed  PubMed Central  Google Scholar 

  • Tsutsui M, Tanaka N, Kawakubo M et al (2010) Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol 44:440–447

    Article  CAS  PubMed  Google Scholar 

  • Vuppalanchi R, Jain AK, Deppe R et al (2014) Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 12:2121–2130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wong VW, Vergniol J, Wong GL et al (2010) Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454–462

    Article  CAS  PubMed  Google Scholar 

  • Wong VW, Vergniol J, Wong GL et al (2012) Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 107:1862–1871

    Article  PubMed  Google Scholar 

  • Younes R, Rosso C, Petta S et al (2018) Usefulness of the index of NASH – ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. Liver Int 38:715–723

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gastroenterologie, Hepatologie u. Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland

    Heike Bantel

  2. Medizinische Klinik I, Sana Kliniken Lübeck, Lübeck, Deutschland

    Matthias J. Bahr

Authors
  1. Heike Bantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias J. Bahr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Heike Bantel .

Editor information

Editors and Affiliations

  1. Medizinische Klinik u. Poliklinik II, Universititätsklinikum Würzburg, ZIM, Würzburg, Bayern, Deutschland

    Andreas Geier

  2. Medizinische Klinik, Universitätsklinikum Bochum GmbH, Bochum, Deutschland

    Ali Canbay

  3. Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Saarland, Deutschland

    Frank Lammert

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bantel, H., Bahr, M.J. (2022). Diagnostik: Blutbasierte Marker. In: Geier, A., Canbay, A., Lammert, F. (eds) Nicht-alkoholische Fettlebererkrankung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62484-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62484-5_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62483-8

  • Online ISBN: 978-3-662-62484-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation